Pharmacokinetics and neurotropic effects of cyclo-L-prolylglycine and its modified analogues
Open Access
- 17 January 2022
- journal article
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 36-41
- https://doi.org/10.37489/2587-7836-2021-2-36-41
Abstract
The review presents the results of studies on the pharmacokinetics, metabolism, and bioavailability of new neurotropic dipeptide cyclo-Lprolilglycine (CPG) and their pharmacological activity. It was shown that the pharmacologically active metabolite of the nootropic drug noopept cyclo-Lprolilglycine (CPG) is an endogenous dipeptide, it is a fragment of the terminal Tripeptide of the insulin-like nerve growth factor IGF-1. Much attention is paid both in Russia and abroad to the development of modified CPG analogues with improved pharmacokinetic properties, enzymatically more stable, better penetrating the BBB, and highly effective when used in micromolar doses. CPG shows neuroprotective activity in ischemic-hypoxic and other brain injuries, in addition, it has a complex of other pharmacological effects and therefore CPG can be considered not only as a potential drug, but also as a basic structure for the development of new neurotropic drugs – analogs of CPG with improved pharmacokinetic properties, greater enzymatic resistance and higher bioavailability for the central nervous system.Keywords
This publication has 17 references indexed in Scilit:
- Maternally Administered Cyclic Glycine-Proline Increases Insulin-Like Growth Factor-1 Bioavailability and Novelty Recognition in Developing OffspringEndocrinology, 2016
- Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate NeurotoxicityBulletin of Experimental Biology and Medicine, 2016
- Regional and Subcellular Localization of Cycloprolylglycine in Rat BrainBulletin of Experimental Biology and Medicine, 2010
- NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal strokeJournal of the Neurological Sciences, 2009
- Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia–ischemia in adult ratsNeuropharmacology, 2007
- Pharmacokinetics of glycine–proline–glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in ratsAnalytical Biochemistry, 2003
- Endogenous Dipeptide Cycloprolylglycine Shows Selective Anxiolytic Activity in Animals with Manifest Fear ReactionBulletin of Experimental Biology and Medicine, 2002
- New endogenous dipeptide cycloprolyl-glycine is similar to piracetam by its mnemotropic selectivityBulletin of Experimental Biology and Medicine, 1999
- Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo‐prolylglycine in rat brainFEBS Letters, 1996
- Bioactive cyclic dipeptidesPeptides, 1995